13F Filings History of Birchview Capital, LP

13F snapshot Latest parsed holdings, value, and filing-period context. 1 signal
Form 13F summary
  • Birchview Capital, LP Form 13F history summarizes parsed U.S.-listed equity disclosures for this manager.
  • Form 13F is generally due within 45 days after each calendar quarter ends.
  • Birchview Capital, LP reported 73 equity holdings with a total reported market value of $175,663,720 for Q1 2026. Top reported holdings included KLAC, BMY, CMPX, LRCX, and STOK.
Manager Names, identifiers, and filing context for this profile. 2 identity fields
Manager signature
John Trottier - CFO/CCO
Manager location
Burlington, VT

Follow Filing Activity

Follow Birchview Capital, LP with Pro and return when a new 13F portfolio filing changes the record on this page.

Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.

Holdings Value

Form 13F evidence

Quarterly portfolio filings

SEC-reported 13F quarters for this filer, ordered by the latest accepted filing.

Latest quarter
Q1 2026
Latest value
$175,663,720
Quarter delta
+$4,865,160
Accepted
15 May 2026, 14:51
Rows shown
1-25 of 52
Quarter Holdings SEC-reported value Bought Sold Net Top Holdings Form Type Accepted by SEC
Q1 2026 73 $175,663,720 +$24,749,821 -$26,324,932 -$1,575,111 KLAC, BMY, CMPX, LRCX, STOK 13F-HR 15 May 2026, 14:51
Q4 2025 68 $170,798,560 +$36,470,603 -$15,053,172 +$21,417,431 KLAC, BMY, CMPX, STOK, LRCX 13F-HR 13 Feb 2026, 10:19
Q3 2025 69 $132,446,155 +$21,995,216 -$50,370,058 -$28,374,842 KLAC, BMY, CORT, PRTA, STOK 13F-HR 13 Nov 2025, 15:30
Q2 2025 71 $100,695,689 +$25,150,660 -$22,741,770 +$2,408,890 BMY, KLAC, CORT, OVV, ACAD 13F-HR 14 Aug 2025, 13:43
Q1 2025 68 $115,021,460 +$4,136,001 -$10,955,099 -$6,819,098 BMY, CORT, ACAD, PRTA, BDSX 13F-HR 15 May 2025, 16:48
Q4 2024 68 $122,779,849 $0 $0 $0 BMY, BDSX, ACAD, ELUT, PRTA New Holdings 30 Jun 2025, 11:19
Q4 2024 68 $122,779,849 +$8,257,134 -$3,971,378 +$4,285,756 BMY, BDSX, ACAD, ELUT, PRTA 13F-HR 14 Feb 2025, 13:56
Q3 2024 61 $115,489,427 $0 $0 $0 BMY, BDSX, ACAD, ELUT, UTHR New Holdings 30 Jun 2025, 11:13
Q3 2024 61 $115,489,427 +$7,205,980 -$13,593,718 -$6,387,738 BMY, BDSX, ACAD, ELUT, UTHR 13F-HR 14 Nov 2024, 14:42
Q2 2024 60 $108,192,580 $0 $0 $0 BMY, BDSX, ELUT, NBIX, SILK ROAD MEDICAL INC New Holdings 30 Jun 2025, 11:09
Q2 2024 60 $108,192,580 +$4,050,884 -$9,716,805 -$5,665,921 BMY, BDSX, ELUT, NBIX, SILK 13F-HR 13 Aug 2024, 16:11
Q1 2024 59 $122,695,509 $0 $0 $0 BMY, NBIX, BDSX, ELUT, ACAD New Holdings 30 Jun 2025, 11:03
Q1 2024 59 $122,695,509 +$2,508,417 -$6,773,350 -$4,264,933 BMY, NBIX, BDSX, ELUT, ACAD 13F-HR 14 May 2024, 15:26
Q4 2023 58 $127,809,273 $0 $0 $0 BMY, NBIX, BDSX, ACAD, PRTA New Holdings 30 Jun 2025, 10:46
Q4 2023 58 $127,809,273 +$6,847,387 -$2,260,923 +$4,586,464 BMY, NBIX, BDSX, ACAD, PRTA 13F-HR 13 Feb 2024, 17:58
Q3 2023 51 $117,708,654 $0 $0 $0 BMY, BDSX, NBIX, PRTA, ACAD New Holdings 30 Jun 2025, 10:34
Q3 2023 51 $117,708,654 +$4,734,865 -$16,859,236 -$12,124,371 BMY, BDSX, NBIX, PRTA, ACAD 13F-HR 14 Nov 2023, 15:49
Q2 2023 54 $133,413,992 +$4,834,134 -$766,169 +$4,067,965 BMY, PRTA, NBIX, BDSX, ACAD 13F-HR 08 Aug 2023, 12:23
Q1 2023 55 $127,725,000 +$2,104,899 -$4,406,000 -$2,301,101 BMY, BDSX, NBIX, PRTA, QDEL 13F-HR 12 May 2023, 10:18
Q4 2022 57 $141,566,000 +$9,381,759 -$6,772,174 +$2,609,585 BMY, BDSX, NBIX, PRTA, ELUT 13F-HR 03 Feb 2023, 12:28
Q3 2022 60 $142,011,000 +$2,742,669 -$7,030,251 -$4,287,582 BMY, ELUT, NBIX, PRTA, QDEL Restatement 28 Nov 2022, 13:44
Q2 2022 60 $137,477,000 +$9,779,625 -$7,135,889 +$2,643,736 BMY, ELUT, NBIX, QDEL, FHTX 13F-HR 12 Aug 2022, 08:04
Q1 2022 63 $138,903,000 +$3,429,891 -$5,215,653 -$1,785,762 BMY, NBIX, ELUT, QDEL, ACAD 13F-HR 13 May 2022, 09:54
Q4 2021 67 $155,071,000 +$15,092,907 -$4,846,350 +$10,246,557 BMY, AXDX, ELUT, QDEL, NBIX 13F-HR 14 Feb 2022, 11:43
Q3 2021 64 $146,958,000 +$4,072,529 -$2,844,661 +$1,227,868 BMY, AXDX, BDSX, QDEL, NBIX 13F-HR 12 Nov 2021, 08:43
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .